Some analysts think this fact alone can provide Xarelto with an edge.Warfarin has a quick-acting antidote for bleeding, vitamin K, Xarelto and its peers do not have one yet.
Europe is an important market because the drug is used mainly in hospitals and so it favors the marketing strategy.I wrote this article myself, and it expresses my own opinions.
While both the Eliquis and Pradaxa pills need to be taken twice a day for stroke prevention, Xarelto is a once daily medication.Connect to the most current information on stocks and bonds on Reuters.com. Finance and investing news on.Success could not come soon enough as Pradaxa is being blamed for more than 1,000 deaths from bleeding around the globe and lawsuits are piling up.
Xarelto is popular among cardiologists who like to prescribe it to new-to-brand patients.The dark horse in the race is Pradaxa, made by the privately held German company, Boehringer Ingelheim.
Biotech Values Message Board: Bayer, JNJ Report Phase-2 Xarelto Data in ACS.Boehringer, on the other hand, is quick to point out that instances of severe bleeding in Pradaxa patients are still less common than in warfarin patients.
Read the latest update on the Xarelto National Litigation given by Judge Fallon in a status conference held on February 23, 2016.
Bristol is changing the marketing strategy for the drug, focusing on presence in hospitals.These newer drugs are supposed to succeed Plavix, one of the largest selling brands of all times and replace inconvenient warfarin which is still widely prescribed.The Institute for Safe Medication Practices (ISMP) in its October 2013 report placed anticoagulant drugs at the top of the list of serious adverse events reported to the FDA, with Pradaxa leading the pack.Longer-term use of the oral blood thinner Xarelto significantly cut the risk of recurrence of potentially life-threatening blood clots with no additional major.
The race is heating up and the participants have different strengths and weaknesses.Eliquis and Pradaxa are both better than warfarin in preventing stroke.Xarelto, otherwise known as rivaroxaban, is a prescribed blood thinner manufactured by Bayer and marketed by Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson.With its superiority in preventing hemorrhagic strokes, Eliquis has the clear lead in terms of safety.